Friedman Edward S, Friedman Paul M, Cohen David E, Washenik Ken
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA.
J Am Acad Dermatol. 2002 Feb;46(2):309-12. doi: 10.1067/mjd.2002.119104.
After more than a decade of use, topical minoxidil solution has proven to be a safe and effective treatment for androgenetic alopecia. However, some patients present with complaints of pruritus and scaling of the scalp. The most common causes of these symptoms include irritant contact dermatitis, allergic contact dermatitis, or an exacerbation of seborrheic dermatitis. Patients suffering from allergic contact dermatitis may benefit from patch testing to determine the causative allergen. Among the patients we patch tested, propylene glycol was found to be the contactant in a majority of cases, not the minoxidil itself. Many of these patients may be candidates for treatment with alternative formulations using other solvents, such as butylene glycol, polysorbate, or glycerol. Although predictive, patch testing results do not ensure that the compounded preparations will be tolerated. Unfortunately, patients found to be allergic to minoxidil are no longer candidates for topical treatment of their alopecia with any preparations of minoxidil.
经过十多年的使用,外用米诺地尔溶液已被证明是治疗雄激素性脱发的一种安全有效的方法。然而,一些患者出现头皮瘙痒和脱屑的症状。这些症状最常见的原因包括刺激性接触性皮炎、过敏性接触性皮炎或脂溢性皮炎加重。患有过敏性接触性皮炎的患者可能受益于斑贴试验以确定致病过敏原。在我们进行斑贴试验的患者中,发现大多数情况下接触剂是丙二醇,而非米诺地尔本身。这些患者中的许多人可能适合使用其他溶剂(如丁二醇、聚山梨酯或甘油)的替代制剂进行治疗。尽管斑贴试验结果具有预测性,但并不能确保复合制剂会被耐受。不幸的是,被发现对米诺地尔过敏的患者不再适合使用任何米诺地尔制剂进行脱发的局部治疗。